Frankfurt - Delayed Quote EUR
MedinCell S.A. (MEB.F)
15.04
-0.04
(-0.27%)
At close: June 13 at 3:29:02 PM GMT+2
Earnings Estimate
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 5 | 5 |
Avg. Estimate | 5.1M | 5.7M | 18.65M | 35.89M |
Low Estimate | 5.1M | 5.7M | 12.72M | 20.87M |
High Estimate | 5.1M | 5.7M | 25M | 48M |
Year Ago Sales | -- | -- | 9.03M | 18.65M |
Sales Growth (year/est) | -- | -- | 106.50% | 92.45% |
EPS Trend
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
MEB.F | -- | -- | -- | -- |
S&P 500 | 13.13% | 2.41% | 7.55% | 14.06% |
Related Tickers
YAG2.F Atossa Therapeutics, Inc.
0.7160
-4.79%
ABVX.PA ABIVAX Société Anonyme
5.79
-7.36%
ANVS Annovis Bio, Inc.
2.8100
-4.42%
CABA Cabaletta Bio, Inc.
1.9900
+10.56%
CPRX Catalyst Pharmaceuticals, Inc.
23.53
-3.13%
SAVA Cassava Sciences, Inc.
2.0500
-3.30%
LYRA Lyra Therapeutics, Inc.
11.34
-4.30%
IOVA Iovance Biotherapeutics, Inc.
2.2400
-3.03%
CRSP CRISPR Therapeutics AG
41.36
+0.19%
CARM Carisma Therapeutics, Inc.
0.4516
-17.62%